Greenfern eyes FDA-approved cannabinoid medicine opportunity as part of multi deal


29 August 2022
 / 

Patients in New Zealand, Australia and the Pacific Islands could soon have access to Syndros, one of only four Food and Drug Administration-approved (FDA) cannabinoid medicines.

Read more